Study of Bevacizumab + Irinotecan + S-1 therapy in metastatic colorectal cancer with KRAS mutant type - Study of Bevacizumab + Irinotecan + S-1 therapy in metastatic colorectal cancer with KRAS mutant type

Tsuchiura kyodo general hospital0 sites25 target enrollmentNovember 30, 2010

Overview

No summary available.

Registry

who.int

Start Date

November 30, 2010

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

•(1\) History of severe allergy (2\) Active double cancer (3\) Severe infectious disease (4\) Intestinal tract paralysis or intestinal obstruction (5\) Uncontrolled hypertention (6\) Sever comorbidity(interstitial lung disease or pulmonary fibrosis, heart failure, renal failure, liver failure, etc) (7\) Massive pleural or abdominal effusion (8\) Patient with the diarrhea (9\) Symptomatic brain metastases (10\) Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test (11\) Severe mental disorder (12\) Systemic administration of corticosteroids (13\) Uric protein 2\+ (14\) Prior radiotherapy for primary and metastases tumors (15\) Thrombosis, cerebral infraction, cardiac infraction or pulmonary infraction within 6 months (16\) Patients who underwent surgery within 4 weeks (17\) Systemic administration of antiplatelet drug (18\) Patients with known bleeding disorders or clotting disorder (19\) Any other cases who are regarded as inadequate for study enrollmet by investigators